Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02626182 · ClinicalTrials.gov registry record · Phase 1
Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF
A Phase 1 study, sponsored by National Jewish Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT02626182: Completed Phase 1 study, sponsored by National Jewish Health.
NCT02626182 is a Phase 1 study that has completed, run by National Jewish Health. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02626182, a Phase 1 study, has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study evaluates the ability of the drug sildenafil to improved exercise capacity, cardiac performance during exercise, and quality of life in patients with moderate to severe CF lung disease. 3/4 of the subjects will receive sildenafil and 1/4 will receive placebo.
Primary Outcome
Change in distance walked between week 1 and week 13 were compared. The difference between the two time points is reported.
Interventions
- DRUG placebo
- DRUG sildenafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-12 |
| Est. Completion | 2018-01-29 |
| Phase | Phase 1 |
What the finished NCT02626182 record still lists
NCT02626182 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02626182 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02626182 about?
NCT02626182 is a clinical study titled "Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF". This study evaluates the ability of the drug sildenafil to improved exercise capacity, cardiac performance during exercise, and quality of life in patients with moderate to severe CF lung disease. 3/4 of the subjects will receive sildenafil and 1/4 will receive placebo.
What is the current status of trial NCT02626182?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2015-12. Estimated completion is 2018-01-29.
What interventions are being tested in trial NCT02626182?
The interventions under investigation include: placebo (DRUG), sildenafil (DRUG).
Who is sponsoring clinical trial NCT02626182?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02626182's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia